MODY (Maturity-Onset Diabetes of the Young) is a monogenic (single-gene) form of diabetes, inherited in an autosomal dominant pattern. Unlike classic type 1 (autoimmune) or typical type 2 (insulin resistance-driven), MODY results from a gene defect that impairs beta-cell function. Many patients are misclassified for years, which matters because treatment and prognosis differ by gene.
When should you suspect MODY?
- Think MODY in a person with:
- Diabetes diagnosed
- Non-obese or only mildly overweight (BMI often normal/near-normal)
- No ketosis or DKA despite years of disease
- Good control on low-dose oral therapy (sometimes diet alone)
- Negative autoantibodies (GAD, IA-2, ZnT8) and preserved C-peptide
- Family history of diabetes across ≥2 generations (autosomal dominant pattern)
Exam/clinic pearl: If a lean 20- or 30-something is still making insulin (C-peptide preserved), has never had DKA, and doesn’t look insulin-resistant—pause and consider MODY.
Why genetic testing changes everything
Confirms the diagnosis (prevents years of misclassification).
Tailors therapy:
HNF1A/HNF4A: switch from insulin/metformin to low-dose sulfonylurea (often dramatic HbA1c improvement).
GCK: usually no pharmacotherapy needed; avoid overtreatment.
Guides family screening: autosomal dominant → test first-degree relatives.
Impacts pregnancy management: particularly for GCK, where treatment depends on whether the fetus inherits the variant.
Which test to order? Request a MODY gene panel, or if phenotype strongly fits, start with HNF1A. In primary care, start with antibodies and C-peptide to justify referral/testing:
Autoantibodies: negative
C-peptide: detectable/preserved (outside the honeymoon period)
